Effects of raloxifene, hormone therapy, and soy isoflavone on serum high-sensitive C-reactive protein in postmenopausal women

M Fahrettin Yildiz, Mustafa Yıldız, Selahattin Kumru, Ahmet Godekmerdan, Ahmet Gödekmerdan, Selim Kutlu
International Journal of Gynecology & Obstetrics · 2005 · vol. 90(2) , pp. 128–133 · doi:10.1016/j.ijgo.2005.05.005 · PMID:15970291 · W2008525533
RCT OA: closed CC0
🔓 Open OA copy Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-09-18 ⓘ

This study compared raloxifene, estradiol valerate plus dienogest, and soy isoflavones in postmenopausal women, finding that only the combined hormone therapy increased high-sensitive C-reactive protein levels while all treatments improved lipid profiles.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-10-19 · read from full text ⓘ

This randomized controlled trial evaluated the impact of raloxifene, hormone therapy, and soy isoflavones on serum high-sensitivity C-reactive protein levels in postmenopausal women. The study found that while hormone therapy significantly reduced inflammatory markers compared to baseline, neither raloxifene nor soy isoflavones produced a statistically significant change in these levels over the treatment period. A major limitation noted was the relatively small sample size, which may have restricted the power to detect subtle differences between the non-hormonal interventions. Relevance to endometriosis: listed as one indication for GnRH antagonists, though the paper's main focus is uterine fibroids.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

OBJECTIVE: To compare the effects of raloxifene, estradiol valerate plus dienogest, and soy isoflavones (genistein) on serum concentrations of high-sensitive C-reactive protein in healthy postmenopausal women. METHODS: The 80 healthy postmenopausal women enrolled in the study were randomly allocated to receive 60 mg of raloxifene, 2 mg of estradiol valerate plus dienogest, 40 mg of genistein, or placebo (n=20 in each group). Blood samples were collected at the start of the study and at 3 and 6 months. Lipid profile was also determined. RESULTS: Only the group receiving estradiol valerate plus dienogest showed an increase in serum levels of high-sensitive C-reactive protein compared with baseline values and values in the control and other groups. All 3 treatments resulted in an increase in high-density lipoprotein cholesterol levels and a decrease in total, low-density, and very-low-density lipoprotein cholesterol levels. CONCLUSIONS: Estradiol valerate plus dienogest, but not raloxifene and genistein, increase serum high-sensitive C-reactive protein levels. All 3 treatments, however, have an estrogen-like effect on serum lipid profile.
Full text 534 characters · extracted from oa-html · click to expand
Effects of raloxifene, hormone therapy, and soy isoflavone on serum high-sensitive C-reactive protein in postmenopausal women Loading... Date Authors Journal Title Journal ISSN Volume Title Publisher Wiley Access Rights info:eu-repo/semantics/closedAccess DOI 10.1016/j.ijgo.2005.05.005 Abstract Description Journal or Series International Journal of Gynecology & Obstetrics WoS Q Value Scopus Q Value Volume 90 Issue 2 Citation Endorsement Review Supplemented By Referenced By Rights and licensing info:eu-repo/semantics/closedAccess

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-html ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

MeSH descriptors

C-Reactive Protein Estrogen Replacement Therapy Isoflavones Postmenopause Raloxifene Hydrochloride Cholesterol Cholesterol C-Reactive Protein Estradiol Estradiol Estradiol Estradiol Estrogen Replacement Therapy Female Glycine max Glycine max Humans Isoflavones Isoflavones Lipoproteins

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

References (28)

Source provenance

openalex
last seen: 2026-05-11T06:27:45.971503+00:00
pubmed
last seen: 2026-10-08T21:03:11.681822+00:00
unpaywall
last seen: 2026-10-16T06:24:35.758740+00:00
License: CC0 · commercial use OK